13 Facts About Esketamine

Esketamine, known as-ketamine or S(+)-ketamine, is the S(+) enantiomer of ketamine, is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression.

Esketamine is the active enantiomer of ketamine in terms of NMDA receptor antagonism and is more potent than racemic ketamine.

Esketamine is used by infusion into a vein for anesthesia and under direct medical supervision as a nasal spray once or twice weekly for depression.

Esketamine is a general anesthetic and is used for similar indications as ketamine.

Esketamine is approved under the brand name Spravato in the form of a nasal spray added to a conventional antidepressant as a therapy for treatment-resistant depression as well as major depressive disorder (MDD) associated with suicidal ideation or behavior in adults in the United States.

Related searches

Esketamine was approved for the treatment of MDD with co-occurring suicidal ideation or behavior on the basis of two short-term phase 3 trials (ASPIRE-1 and -2) of esketamine nasal spray added to a conventional antidepressant.

Esketamine is approximately twice as potent an anesthetic as racemic ketamine.

Esketamine was introduced for medical use as an anesthetic in Germany in 1997, and was marketed in other countries.

Esketamine received a breakthrough designation from the FDA for treatment-resistant depression in 2013 and major depressive disorder (MDD) with accompanying suicidal ideation in 2016.

Esketamine is the generic name of the drug and its INN and BAN, while esketamine hydrochloride is its BANM.

Esketamine is sold under the brand name Spravato for use as an antidepressant and the brand names Eskesia, Ketanest, Ketanest S, Ketanest-S, Keta-S for use as an anesthetic, among others.

Esketamine is marketed as an antidepressant in the United States; and as an anesthetic in the European Union.

Esketamine is a Schedule III controlled substance in the United States.